Burnett, AK;
Das Gupta, E;
Knapper, S;
Khwaja, A;
Sweeney, M;
Kjeldsen, L;
Hawkins, T;
... Russell, NH; + view all
(2018)
The Addition Of The MTORr Inhibitor, Everolimus, To Consolidation Therapy In Acute Myeloid Leukaemia: Experience From The UK NCRI AML17 Trial.
Haematologica
10.3324/haematol.2018.189514.
(In press).
Preview |
Text
Khwaja_haematol.2018.189514.full copy.pdf - Accepted Version Download (2MB) | Preview |
Abstract
As part of the UK NCRI AML17 trial, adult acute myeloid leukaemia patients in remission could be randomised to receive the mTOR inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty-nine patients were randomised (2:1) to receive everolimus or not for a maximum of 84 days between chemotherapy courses. The primary endpoint was relapse free survival (RFS). At 5 years there was no difference in Relapse Free Survival (29% vs 40%; OR 1.19 (0.9-1.59) p=0.2), cumulative incidence of relapse (60% vs 54%: OR 1.12( 0.82-1.52): p=0.5) or overall survival (45% vs 58%: OR 1.3 (0.94-1.81): p=0.11). The independent Data Monitoring Committee advised study termination after randomisation of 339 of the intended 600 patients due to an excess mortality in the everolimus arm without any evidence of beneficial disease control. Dose delivery of everolimus was variable, but there was no evidence of clinical benefit in patients with adequate dose delivery compared with no treatment. This study suggests that the addition of mTOR inhibition to chemotherapy provides no benefit. Clinica Trial: ISRCTN55675535
| Type: | Article |
|---|---|
| Title: | The Addition Of The MTORr Inhibitor, Everolimus, To Consolidation Therapy In Acute Myeloid Leukaemia: Experience From The UK NCRI AML17 Trial |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3324/haematol.2018.189514 |
| Publisher version: | http://dx.doi.org/10.3324/haematol.2018.189514 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | acute myeloid leukemia, clinical trials, mTOR inhibition |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10052058 |
Archive Staff Only
 |
View Item |
